Article info
PDFLetter
Letter to the Editor: In response to a recent non-inferiority trial of bupivacaine alone versus liposomal bupivacaine plus bupivacaine in interscalene blocks for total shoulder arthroplasty
- Correspondence to Dr Roy Winston, Pacira BioSciences, Inc., Tampa, FL 33609, USA; roy.winston{at}pacira.com
Citation
Letter to the Editor: In response to a recent non-inferiority trial of bupivacaine alone versus liposomal bupivacaine plus bupivacaine in interscalene blocks for total shoulder arthroplasty
Publication history
- Received January 17, 2023
- Accepted January 18, 2023
- First published February 8, 2023.
Article Versions
- You are currently viewing a Previous version of this article (23 June 2023).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© American Society of Regional Anesthesia & Pain Medicine 2023. Re-use permitted under CC BY-NC. No commercial re-use. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, an indication of whether changes were made, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.